Previous 10 | Next 10 |
SAN FRANCISCO and SAN DIEGO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Kinnate&...
SAN FRANCISCO and SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan , will participate in the Piper Sandler Heartl...
SAN FRANCISCO and SAN DIEGO, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan , will participate in a fireside chat at the We...
Gainer: Kinnate Biopharma ( KNTE ) +5% . Kezar Life Sciences ( KZR ) +5% . BridgeBio Pharma ( BBIO ) +5% . Stronghold Digital Mining ( SDIG ) +3% . IDEAYA Biosciences ( IDYA ) +3% . Losers: Advanced Emissions Solutions ( ...
Kinnate Biopharma press release ( NASDAQ: KNTE ): Q2 GAAP EPS of -$0.62 beats by $0.03 . As of June 30, 2022, the total of cash and cash equivalents and investments was $279.6 million, exclusive of Kinnjiu’s cash. For further details see: Kinnate Bioph...
Phase 1 clinical trial for KIN-2787, the company’s investigational pan-RAF inhibitor, was initiated in Taiwan by Kinnjiu Biopharma Inc., Kinnate’s China joint venture U.S. Food and Drug Administration granted Orphan Drug Designation for KIN-2787 for the tre...
SAN FRANCISCO and SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan , will participate in the “Bullseye - Ta...
SAN FRANCISCO and SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, t...
Kinnate Biopharma press release (NASDAQ:KNTE): Q1 GAAP EPS of -$0.61. As of March 31, 2022, the total of cash and cash equivalents and investments was $302.4 million, exclusive of Kinnjiu’s cash. Existing cash and cash equivalents and investments as of March 31, 2022 with budget reallo...
Initial monotherapy data from ongoing Phase 1 KN-8701 clinical trial expected in the fourth quarter of 2022 Announces initiation of the combination portion of Phase 1 KN-8701 clinical trial to evaluate its pan-RAF inhibitor, KIN-2787, with binimetinib in NRAS-mutant melanoma ...
News, Short Squeeze, Breakout and More Instantly...
Kinnate Biopharma Inc. Company Name:
KNTE Stock Symbol:
NASDAQ Market:
Kinnate Biopharma Inc. Website:
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced th...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...